Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.

Abstract

BACKGROUND:

Angiogenesis-related marker vascular cell adhesion molecule-1 (VCAM-1) has been shown to be elevated in urothelial carcinoma of the bladder (UCB), but its predictive/prognostic role has not been determined. Thus, this study aimed to investigate the predictive/prognostic role of VCAM-1 for patients who have UCB treated with radical cystectomy (RC).

METHODS:

The study enrolled 1036 patients with clinically non-metastatic advanced UCB who underwent RC, and plasma VCAM-1 was evaluated preoperatively. The correlation of plasma VCAM-1 with pathologic and survival outcomes was assessed using binominal logistic regression and multivariable Cox regression analyses. Discrimination was assessed using the area under the curve and concordance indices. The clinical net benefit was evaluated using decision curve analysis (DCA).

RESULTS:

Preoperative VCAM-1 was significantly elevated in patients with adverse pathologic features. Higher VCAM-1 levels were independently associated with increased risk of lymph-node-metastasis (LNM), ≥pT3 disease, and non-organ-confined disease (NOCD (p < 0.001 for each). Preoperative plasma VCAM-1 was independently associated with recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in pre- and postoperative multivariable models. Adding VCAM-1 to these predictive models improved their discriminatory ability to predict all outcomes by a significant margin. In the DCA, VCAM-1 addition to the reference models for prediction of LNM, NOCD, RFS, and CSS resulted in relevant improvement.

CONCLUSIONS:

Elevated plasma VCAM-1 was associated with biologically and clinically aggressive UCB disease features. After validation, preoperative VCAM-1 may serve as a biomarker to help identify patients likely to benefit from intensified/multimodal therapy. In addition, VCAM-1 improved the discriminatory power of predictive/prognostic models and can be used to refine personalized clinical decision-making.

• Authors: Keiichiro Mori, Victor M Schuettfort, Satoshi Katayama, Ekaterina Laukhtina, Benjamin Pradere, Fahad Quhal, Reza Sari Motlagh, Hadi Mostafaei, Nico C Grossmann, Pawel Rajwa, Jeremy Yc Teoh, Irene Resch, Harun Fajkovic, Marco Moschini, David D'andrea, Mohammad Abufaraj, Pierre I Karakiewicz, Yair Lotan, Douglas Scherr, Shin Egawa, Eva Compérat, Shahrokh F Shariat, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)
• Journal: Annals of surgical oncology (Ann Surg Oncol) Vol. 29 Issue 8 Pg. 5307-5316 (Aug 2022) ISSN: 1534-4681 [Electronic] United States
• PMID: 35347517 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Vascular Cell Adhesion Molecule-1

Topics

• Carcinoma, Transitional Cell (pathology, surgery)
• Cystectomy
• Humans
• Lymphatic Metastasis
• Prognosis
• Retrospective Studies
• Treatment Outcome
• Urinary Bladder (pathology)
• Urinary Bladder Neoplasms (pathology)
• Vascular Cell Adhesion Molecule-1